Preface

In 2023, we are in our 23rd year for Current Molecular Medicine. Based on our excellent progress and the associated high reputation gained during these years, we are happy to announce that the journal’s impact factor increased to 2.616. To maintain such high impact for the work of the authors by submitting to our high-quality journal with wide readership and rapid processing times, CMM will further improve the publishing experience and help to achieve maximum scientific impact.

Similar to as before, in 2023 we will publish comprehensive and critical reviews of molecular medicinal interests as well as a limited number of original research articles on special hot topics. First of all, I would like to express my sincere gratitude for the time and expert efforts of all external peer-reviewers to provide their recommendations regarding the quality of the submitted articles as well as the corresponding authors who responded to the concerns of the reviewers in bringing their studies to publication. With our very thorough review process and high quality manuscripts, the editorial board expect further increase in the impact factor of the journal in the upcoming years.

The first issue of Current Molecular Medicine in 2023 contains eight high quality articles (6 review papers and 2 research articles) covering a broad range of molecular medicine. The issue starts with a comprehensive review article about free radicals and oxidative stress with special focus on cell cycle regulation. The following five review papers are focusing on the following important topics: determinative role of cytokines in retinopathy of prematurity; altered expression of tripartite motif-containing proteins-inimical outcome and inimitable oncogenic function in breast cancer with diverse carcinogenic hallmarks; a research update on the pathophysiological mechanisms of heart failure with preserved ejection fraction; an insight into the molecular mechanism of mitochondrial toxicant-induced neuronal apoptosis in Parkinson’s disease and finally a very timely review about molecular pathways, targeted therapies and proteomic investigations of colorectal cancer. These review papers are followed by two original research articles, the first is on breviscapine, a flavonoid, combined with bone marrow mesenchymal stem cells reduces Aβ deposition in rat with Alzheimer’s disease by regulating circular RNA ciRS-7. The closing research article of the issue enlightens the cyclosporine ameliorates silica-induced autoimmune hepatitis in rat model by altering the expression of toll-like receptor-4, interleukin-2 and tumor necrosis factor-alpha. As the Editor in Chief, I do believe that this collection of papers represents a great kick-off for the upcoming year.

At the beginning of 2023, I would like to express my sincere gratitude to the Editorial Board Members and the Editorial Team of Bentham Science Publishers for their assistance and continuous support to the progress of the journal. I also greatly appreciate the help of my colleague Dr László Hajba during the editorial duties. We look forward to the continued support of our readers and contributing authors with the belief that 2023 will be another fruitful year for the journal.

With this, I would like to wish you all a Happy and Healthy New Year.

András Guttman
Editor-in-Chief
Current Molecular Medicine
Horváth Csaba Memorial Laboratory of Bioseparation Sciences,
University of Debrecen
Debrecen, Hungary
E-mail: andrasguttman@gmail.com

DISCLAIMER: The above article has been published, as is, ahead-of-print, to provide early visibility but is not the final version. Major publication processes like copyediting, proofing, typesetting and further review are still to be done and may lead to changes in the final published version, if it is eventually published. All legal disclaimers that apply to the final published article also apply to this ahead-of-print version.